Fibrobiologics Inc（FBLG）のニュースとイベントFBLGFibrobiologics Inc

FibroBiologics Receives Notice of Acceptance for Australian Patent

FibroBiologics announced that IP Australia has issued a Notice of Acceptance for Australian Patent Application No. 2024200985, titled "Cellular Blend for the Regeneration of Chondrocytes or Cartilage Type Cells." The accepted application contains claims directed to methods of generating chondrocytes or chondrocyte-like cells and repairing or regenerating cartilage in a degenerated spinal disc by delivering fibroblasts together with platelet rich plasma and components of the nucleus pulposus, including nucleus pulposus conditioned media. A Notice of Acceptance, the Australian equivalent of a notice of allowance, indicates that IP Australia has completed its examination of the application and that the patent application is expected to proceed to grant following publication. The intervertebral disc depends on the nucleus pulposus, the gel-like core of the disc, to retain water and distribute mechanical load across the spine. In a healthy disc, the nucleus pulposus is populated by notochordal cells, chondrocyte-like, and fibroblast-like cells that produce proteoglycans, aggrecan, and collagen. As the disc degenerates, these cells decline in number, matrix production falls, and the disc loses hydration and height, all of which contribute to chronic lower back pain and loss of function. A method of generating chondrocytes or chondrocyte-like cells by providing to a degenerated disc one or more components from the nucleus pulposus, including nucleus pulposus conditioned media, together with a composition comprising fibroblasts and platelet rich plasma, including the utilization of transforming growth factor beta-1, or TGFB1, notochordal cells, small chondrocyte-like cells, collagen fibrils, proteoglycans, and aggrecan; A method of improving the condition of an aged disc by providing a cell blend comprising fibroblasts and platelet rich plasma that reflects the cellular composition found in a disc that has not begun the degenerative process, optionally supplemented with stem cells, adipocytes, notochordal cells, or other supporting cell types.

FibroBiologics Files Patent Application for New Cell-Based Technology

FibroBiologics announced that it has filed a U.S. patent application covering a new cell-based technology designed to continuously produce peptides such as GLP-1, GIP and GLP-2 inside the body. The patent application describes engineering living cells to act like tiny peptide factories inside the body. These cells would be grouped together into small three-dimensional structures called spheroids or organoids. Once administered to a patient, they are designed to continuously produce and release a therapeutic peptide.

FibroBiologics Granted U.S. Patent No. 12,721,866

FibroBiologics announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,721,866, titled "Therapeutic Use of Fibroblasts for Use in Wound Healing." The patent, issued on September 1, 2026, covers methods of treating and accelerating the healing of wounds by topically administering a therapeutically effective amount of a composition comprising fibroblasts and fibroblast-derived materials.